Desmopressin - DDAVP oral tablets

The Ferring tablet label contraindicates CrCl below 50 mL/min and hyponatremia/history. Fluid restriction, clinical supervision and surveillance for hyponatremia remain essential, particularly in pediatric and geriatric patients. Central-DI response is followed using urine volume and osmolality; this does not replace safety assessment. Primary-nocturnal-enuresis treatment should be interrupted during fluid/electrolyte-disturbing illness and circumstances increasing water intake. This conventional-tablet summary does not import the injection's laboratory timetable or convert between dosage forms.

The dated tablet mirror contraindicates CrCl below 50 mL/min and hyponatremia or its history. It retains fluid restriction and special caution in children and older adults. For primary nocturnal enuresis, interrupt therapy during acute fluid/electrolyte-disturbing illness or circumstances associated with increased water intake. The page prints July 2007 revision information; its renal wording is retained as an attributed historical mirror, not evidence that every prescribing section is current.